Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Regeneron Pharmaceuticals leans bullish right now: more is going right than wrong.
- What's working
- It carries less debt and has more breathing room than most other healthcare companies.
- Worth watching
- No major weak spots stand out in the data right now.
Analyst price target
~12-month · 27 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions…
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15,410
- Headquarters
- Tarrytown, NY
Similar stocks
What’s behind the score
Valuation
P/E 19.6 — lower than 79% of Healthcare peers
P/B 2.5 — lower than 68% of Healthcare peers
P/S 5.2 — lower than 47% of Healthcare peers
EV/EBITDA 15.7 — lower than 43% of Healthcare peers
EV/Revenue 4.7 — lower than 50% of Healthcare peers
PEG 1.4 — lower than 63% of Healthcare peers
FCF yield 3.8% — higher than 52% of Healthcare peers
Profitability & quality
Gross margin 44.5% — higher than 30% of Healthcare peers
Operating margin 33.1% — higher than 73% of Healthcare peers
Net margin 27.9% — higher than 90% of Healthcare peers
ROE 14.0% — higher than 59% of Healthcare peers
ROA 6.5% — higher than 55% of Healthcare peers
Free cash flow is 71% of reported net income
Financial health
Debt/equity 0.1 — lower than 93% of Healthcare peers
Current ratio 3.33 — higher than 93% of Healthcare peers
Quick ratio 2.63 — higher than 93% of Healthcare peers
Cash/debt 2.95 — higher than 90% of Healthcare peers
Debt/EBITDA 0.58 — lower than 86% of Healthcare peers
Growth
Revenue growth 16.7% YoY — higher than 90% of Healthcare peers
Earnings growth -4.5% YoY — higher than 27% of Healthcare peers
Ownership & investor activity
Payout ratio 9.0% — somewhat unusual vs Healthcare peers
Net insider buying, +0.8% of insider shares
Institutions net sold, -12.8% of shares held
Insiders hold 2.1% of shares outstanding
2.2% of float sold short
Momentum
Mixed vs its moving averages
76% of the way from its 52-week low to high